<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20250314061204&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20250314061204&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 14 Mar 2025 10:12:05 +0000</lastbuilddate>
<pubDate>Thu, 13 Mar 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>An update on the ESC Council on Cardiovascular Genomics: out from the niche into the open</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40079516/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 13:ehaf068. doi: 10.1093/eurheartj/ehaf068. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40079516/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40079516</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf068>10.1093/eurheartj/ehaf068</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40079516</guid>
<pubDate>Thu, 13 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Stefan Kääb</dc:creator>
<dc:creator>Antoine Bondue</dc:creator>
<dc:date>2025-03-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>An update on the ESC Council on Cardiovascular Genomics: out from the niche into the open</dc:title>
<dc:identifier>pmid:40079516</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf068</dc:identifier>
</item>
<item>
<title>Leaders in cardiology: Holger Thiele</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40079513/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 13:ehaf010. doi: 10.1093/eurheartj/ehaf010. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40079513/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40079513</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf010>10.1093/eurheartj/ehaf010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40079513</guid>
<pubDate>Thu, 13 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2025-03-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Leaders in cardiology: Holger Thiele</dc:title>
<dc:identifier>pmid:40079513</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf010</dc:identifier>
</item>
<item>
<title>TAVI or TAVR: it is time to use a single standardized acronym for percutaneous aortic valve implantation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40079495/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 13:ehaf048. doi: 10.1093/eurheartj/ehaf048. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40079495/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40079495</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf048>10.1093/eurheartj/ehaf048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40079495</guid>
<pubDate>Thu, 13 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Ciro Indolfi</dc:creator>
<dc:creator>Giovanni Esposito</dc:creator>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:date>2025-03-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>TAVI or TAVR: it is time to use a single standardized acronym for percutaneous aortic valve implantation</dc:title>
<dc:identifier>pmid:40079495</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf048</dc:identifier>
</item>
<item>
<title>March2 Alleviates Aortic Aneurysm/Dissection by Regulating PKM2 Polymerization</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40079144/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings demonstrated that March2 is a novel endogenous defender that prevents AAD by inhibiting vascular smooth muscle cell apoptosis, suggesting that March2 represents a potential therapeutic target for AAD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Mar 13. doi: 10.1161/CIRCRESAHA.124.325049. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Aortic aneurysm/dissection (AAD) is a life-threatening disease lacking effective pharmacological treatment. Protein ubiquitination plays a pivotal role in cardiovascular diseases. However, the possible contribution of the E3 ubiquitin ligase March2 (membrane-associated RING finger protein 2) to the cause of AAD remains elusive.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Integrated single-cell RNA sequencing analysis was conducted in human AAD tissues. Based on the screening results, we generated a mouse line of smooth muscle cell-specific March2 knockout. β-Aminopropionitrile monofumarate was used to establish AAD. Cleavage under targets and tagmentation and cleavage under targets and tagmentation-quantitative polymerase chain reaction were performed to identify possible target genes for histone H3K18 lactylation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: March2 expression was downregulated in aorta from patients with AAD or β-aminopropionitrile monofumarate-induced AAD mice. β-Aminopropionitrile monofumarate-induced AAD was significantly accentuated in March2 global (March2<sup>-/-</sup>) and vascular smooth muscle cell-specific deletion (March2<sup>fl/fl</sup>; Tagln<sup>Cre</sup>) mice, whereas the AAD pathology was rescued by rAAV9-SM22α-March2 (recombinant adeno-associated virus serotype 9 expressing Flag-tagged March2 under SM22α promoter). March2 interacted with PKM2 (pyruvate kinase M2) to promote K33-linked polyubiquitination. Deficiency of March2 lessened PKM2 dimer-to-tetramer conversion in AAD and overtly exacerbated AAD-induced histone H3K18 lactylation in vascular smooth muscle cells by fostering glucose metabolism reprogramming, thereby promoting p53-driven apoptotic transcriptional response-a hallmark of AAD pathogenesis. TEPP-46, a PKM2-specific activator, pronouncedly alleviated March2 deficiency-deteriorated AAD pathology.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings demonstrated that March2 is a novel endogenous defender that prevents AAD by inhibiting vascular smooth muscle cell apoptosis, suggesting that March2 represents a potential therapeutic target for AAD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40079144/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40079144</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325049>10.1161/CIRCRESAHA.124.325049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40079144</guid>
<pubDate>Thu, 13 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Yiran E Li</dc:creator>
<dc:creator>Shuolin Liu</dc:creator>
<dc:creator>Litao Wang</dc:creator>
<dc:creator>Yuxin Du</dc:creator>
<dc:creator>Lin Wu</dc:creator>
<dc:creator>Haoran Chen</dc:creator>
<dc:creator>Tingfang Zhu</dc:creator>
<dc:creator>Jie Lin</dc:creator>
<dc:creator>Shengjun Xiong</dc:creator>
<dc:creator>Yayu Wang</dc:creator>
<dc:creator>Qijun Zheng</dc:creator>
<dc:creator>Rongjun Zou</dc:creator>
<dc:creator>Ling Lin</dc:creator>
<dc:creator>Zheyun Li</dc:creator>
<dc:creator>Lixin Wang</dc:creator>
<dc:creator>Junbo Ge</dc:creator>
<dc:creator>Jun Ren</dc:creator>
<dc:creator>Yingmei Zhang</dc:creator>
<dc:date>2025-03-13</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>March2 Alleviates Aortic Aneurysm/Dissection by Regulating PKM2 Polymerization</dc:title>
<dc:identifier>pmid:40079144</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325049</dc:identifier>
</item>
<item>
<title>Direct-to-Consumer Genetic Testing for Cardiovascular Disease: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40079117/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>Despite insufficient evidence to support direct-to-consumer genetic testing in routine clinical care, cardiovascular clinicians increasingly face questions about its utility and interpretation because individuals can purchase these tests directly from laboratories. A burgeoning marketplace offers an expanding array of testing options. In many cases, direct-to-consumer genetic testing advertises information that could inform one's risk of heritable disease, including insight into having a genetic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 13. doi: 10.1161/CIR.0000000000001304. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite insufficient evidence to support direct-to-consumer genetic testing in routine clinical care, cardiovascular clinicians increasingly face questions about its utility and interpretation because individuals can purchase these tests directly from laboratories. A burgeoning marketplace offers an expanding array of testing options. In many cases, direct-to-consumer genetic testing advertises information that could inform one's risk of heritable disease, including insight into having a genetic predisposition to cardiovascular disease or data about gene-drug interactions that could affect response to cardiovascular medications. Navigating clinical questions about direct-to-consumer genetic testing involves understanding the evolution and oversight of the marketplace; the scope of direct-to-consumer genetic testing offerings; and the risks, benefits, and limitations of said testing. In this American Heart Association scientific statement, we summarize the state of the direct-to-consumer genetic testing industry, review types of cardiovascular genetic information that may be included in direct-to-consumer genetic testing, describe approaches to evaluate test quality, and provide resources for clinicians navigating questions about direct-to-consumer genetic testing. If direct-to-consumer genetic test information is used in clinical care, care should be taken to assess the limitations of the test, to contextualize the information specifically to the patient, and to corroborate potentially actionable monogenic findings.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40079117/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40079117</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001304>10.1161/CIR.0000000000001304</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40079117</guid>
<pubDate>Thu, 13 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Leland E Hull</dc:creator>
<dc:creator>Aaron W Aday</dc:creator>
<dc:creator>Quan M Bui</dc:creator>
<dc:creator>Jasmine A Luzum</dc:creator>
<dc:creator>James M Muchira</dc:creator>
<dc:creator>Hannah Wand</dc:creator>
<dc:creator>C Anwar A Chahal</dc:creator>
<dc:creator>Mina K Chung</dc:creator>
<dc:creator>Anne E Kwitek</dc:creator>
<dc:creator>Silvana Molossi</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>American Heart Association Data Science and Precision Medicine Committee of the Council on Genomic and Precision Medicine and Council of Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease</dc:creator>
<dc:date>2025-03-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Direct-to-Consumer Genetic Testing for Cardiovascular Disease: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:40079117</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001304</dc:identifier>
</item>
<item>
<title>Reply: The Impact of Patiromer on Heart Failure Treatment With Angiotensin Inhibitors and MRAs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074478/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):e115. doi: 10.1016/j.jacc.2024.12.029.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074478/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40074478</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.029>10.1016/j.jacc.2024.12.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074478</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Jeffrey Budden</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: The Impact of Patiromer on Heart Failure Treatment With Angiotensin Inhibitors and MRAs</dc:title>
<dc:identifier>pmid:40074478</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.029</dc:identifier>
</item>
<item>
<title>The Impact of Patiromer on Heart Failure Treatment With Angiotensin Inhibitors and MRAs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074477/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):e113. doi: 10.1016/j.jacc.2024.09.1248.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074477/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40074477</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1248>10.1016/j.jacc.2024.09.1248</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074477</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Wei-Zhen Tang</dc:creator>
<dc:creator>Qin-Yu Cai</dc:creator>
<dc:creator>Yun-Ren Pan</dc:creator>
<dc:creator>Tai-Hang Liu</dc:creator>
<dc:creator>Ying-Bo Li</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Impact of Patiromer on Heart Failure Treatment With Angiotensin Inhibitors and MRAs</dc:title>
<dc:identifier>pmid:40074477</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1248</dc:identifier>
</item>
<item>
<title>Reply: Urinary Metal Levels and Coronary Artery Calcification: Potential Confounders</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074476/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):e111. doi: 10.1016/j.jacc.2024.11.050.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074476/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40074476</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.050>10.1016/j.jacc.2024.11.050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074476</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Katlyn E McGraw</dc:creator>
<dc:creator>Steven Shea</dc:creator>
<dc:creator>Ana Navas-Acien</dc:creator>
<dc:creator>Tiffany R Sanchez</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Urinary Metal Levels and Coronary Artery Calcification: Potential Confounders</dc:title>
<dc:identifier>pmid:40074476</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.050</dc:identifier>
</item>
<item>
<title>Environmental Metal Exposure and Cardiovascular Disease Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074475/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):e109. doi: 10.1016/j.jacc.2024.10.127.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074475/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40074475</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.127>10.1016/j.jacc.2024.10.127</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074475</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Jixuan Wu</dc:creator>
<dc:creator>Zili Zhang</dc:creator>
<dc:creator>Lei Zhang</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Environmental Metal Exposure and Cardiovascular Disease Risk</dc:title>
<dc:identifier>pmid:40074475</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.127</dc:identifier>
</item>
<item>
<title>Urinary Metal Levels and Coronary Artery Calcification: Potential Confounders</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074474/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):e107. doi: 10.1016/j.jacc.2024.09.1247.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074474/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40074474</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1247>10.1016/j.jacc.2024.09.1247</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074474</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Richard A Chazal</dc:creator>
<dc:creator>Juan Lopez-Mattei</dc:creator>
<dc:creator>Juan Gaztañaga</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Urinary Metal Levels and Coronary Artery Calcification: Potential Confounders</dc:title>
<dc:identifier>pmid:40074474</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1247</dc:identifier>
</item>
<item>
<title>Clinical Effect of Genetic Testing in Inherited Cardiovascular Diseases: A 14-Year Retrospective Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074473/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Genetic testing in a clinical context identified a disease-causing variant in 24% of probands, thus highlighting the high yield of rare variant genetic testing. Beyond the impact on family screening, the genetic testing result affected clinical management. Access to allele frequency data from a local population refines variant interpretation and classification.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):988-999. doi: 10.1016/j.jacc.2024.11.025.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The clinical impact of genetic testing in a contemporary real-life cohort of patients with heritable cardiomyopathies or arrhythmias is not well defined. Additionally, the genetic spectrum of these conditions in the French-Canadian population is unknown, and interpretation of genetic variants can be challenging because of a known founder effect.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to evaluate the clinical utility of arrhythmia and cardiomyopathy genetic testing and assess the utility of allele frequency data from a local reference population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The study included consecutive probands seen at the Montreal Heart Institute Cardiovascular Genetics Centre (Montreal, Quebec, Canada) for suspected heritable cardiomyopathies or arrhythmias for which both clinical data and genetic testing results were available. The study analyzed the enrichment of recurrent rare genetic variants by comparing their prevalence in the case cohort with that of a local population cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 2,062 probands (mean age at diagnosis 47 ± 17 years) were included. Overall, genetic testing identified a pathogenic/likely pathogenic (P/LP) variant in 496 (24%) probands. A total of 9 variants had their classification changed after comparing their prevalence (case control enrichment) using a local population-based cohort. Genetic testing resulted in diagnostic refinement with a potential impact on clinical management in 168 (8%) probands.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Genetic testing in a clinical context identified a disease-causing variant in 24% of probands, thus highlighting the high yield of rare variant genetic testing. Beyond the impact on family screening, the genetic testing result affected clinical management. Access to allele frequency data from a local population refines variant interpretation and classification.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074473/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40074473</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.025>10.1016/j.jacc.2024.11.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074473</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Steffany Grondin</dc:creator>
<dc:creator>Benjamin Neveu</dc:creator>
<dc:creator>Iness Soltani</dc:creator>
<dc:creator>Ahmed Amine Alaoui</dc:creator>
<dc:creator>Alexander Messina</dc:creator>
<dc:creator>Laurence Gaumond</dc:creator>
<dc:creator>Fabrice Demonière</dc:creator>
<dc:creator>Ken Sin Lo</dc:creator>
<dc:creator>Amélie Jeuken</dc:creator>
<dc:creator>Catherine Barahona-Dussault</dc:creator>
<dc:creator>Guillaume Sylvain-Drolet</dc:creator>
<dc:creator>Laura Robb</dc:creator>
<dc:creator>Johannie Gagnon</dc:creator>
<dc:creator>Evelyne Naas</dc:creator>
<dc:creator>Valérie-Anne Codina-Fauteux</dc:creator>
<dc:creator>Diana Margarita Victoria Moron</dc:creator>
<dc:creator>Sandra Therrien-Laperrière</dc:creator>
<dc:creator>Valérie Hay</dc:creator>
<dc:creator>Guillaume Lettre</dc:creator>
<dc:creator>Marie-A Chaix</dc:creator>
<dc:creator>Léna Rivard</dc:creator>
<dc:creator>Geneviève Giraldeau</dc:creator>
<dc:creator>Philippe L L'Allier</dc:creator>
<dc:creator>Patrick Garceau</dc:creator>
<dc:creator>Maxime Tremblay-Gravel</dc:creator>
<dc:creator>Julia Cadrin-Tourigny</dc:creator>
<dc:creator>Mario Talajic</dc:creator>
<dc:creator>Julie Amyot</dc:creator>
<dc:creator>Rafik Tadros</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clinical Effect of Genetic Testing in Inherited Cardiovascular Diseases: A 14-Year Retrospective Study</dc:title>
<dc:identifier>pmid:40074473</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.025</dc:identifier>
</item>
<item>
<title>Do Potassium Binders Block Both the Benefits and the Risks of Mineralocorticoid Receptor Antagonists in Heart Failure?: The Four Anti-Aldosterone Myths</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074472/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):985-987. doi: 10.1016/j.jacc.2025.01.011.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074472/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40074472</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.011>10.1016/j.jacc.2025.01.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074472</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Do Potassium Binders Block Both the Benefits and the Risks of Mineralocorticoid Receptor Antagonists in Heart Failure?: The Four Anti-Aldosterone Myths</dc:title>
<dc:identifier>pmid:40074472</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.011</dc:identifier>
</item>
<item>
<title>The Value of Case-Based Learning in Cardiovascular Medicine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074471/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):1058. doi: 10.1016/j.jacc.2025.02.005.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074471/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40074471</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.005>10.1016/j.jacc.2025.02.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074471</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Value of Case-Based Learning in Cardiovascular Medicine</dc:title>
<dc:identifier>pmid:40074471</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.005</dc:identifier>
</item>
<item>
<title>Best Practices for Imaging of Transcatheter Valve Failure: An Update From the Heart Valve Collaboratory</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074470/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>This updated Heart Valve Collaboratory framework addresses the growing concern for transcatheter valve failure (TVF) following transcatheter aortic valve replacement (TAVR). With the increasing volume of redo-TAV and surgical TAV explantation, there is a critical need for standardized pathways and protocols for evaluating TVF using echocardiography and cardiac computed tomography (CT) angiography. This document clarifies prior definitions of bioprosthetic valve deterioration and bioprosthetic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):1042-1055. doi: 10.1016/j.jacc.2024.12.017.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This updated Heart Valve Collaboratory framework addresses the growing concern for transcatheter valve failure (TVF) following transcatheter aortic valve replacement (TAVR). With the increasing volume of redo-TAV and surgical TAV explantation, there is a critical need for standardized pathways and protocols for evaluating TVF using echocardiography and cardiac computed tomography (CT) angiography. This document clarifies prior definitions of bioprosthetic valve deterioration and bioprosthetic valve failure in a practical, imaging directed context for TAVR. It discusses various imaging modalities for diagnosing TVF, including echocardiography, cardiac CT angiography, cardiac magnetic resonance, and positron emission tomography/CT. Recommendations are provided on the systematic imaging for: 1) follow-up post-TAVR; 2) procedural planning for redo-TAV; and 3) post-redo-TAV, emphasizing the importance of regular monitoring and the need for comprehensive imaging data to optimize patient outcomes in the lifetime management of aortic valve disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074470/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40074470</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.017>10.1016/j.jacc.2024.12.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074470</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Omar K Khalique</dc:creator>
<dc:creator>Syed Zaid</dc:creator>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:creator>Mohamed Abdel-Wahab</dc:creator>
<dc:creator>Miriama Akodad</dc:creator>
<dc:creator>Vinayak N Bapat</dc:creator>
<dc:creator>Jeroen J Bax</dc:creator>
<dc:creator>Daniel J Blackman</dc:creator>
<dc:creator>Philipp Blanke</dc:creator>
<dc:creator>Sabine Bleiziffer</dc:creator>
<dc:creator>Davide Capodanno</dc:creator>
<dc:creator>Joao L Cavalcante</dc:creator>
<dc:creator>Lakshmi P Dasi</dc:creator>
<dc:creator>Ole De Backer</dc:creator>
<dc:creator>Matthiew De Beuel</dc:creator>
<dc:creator>Alison Duncan</dc:creator>
<dc:creator>Marc R Dweck</dc:creator>
<dc:creator>Miho Fukui</dc:creator>
<dc:creator>Aakriti Gupta</dc:creator>
<dc:creator>Kentaro Hayashida</dc:creator>
<dc:creator>Howard C Herrmann</dc:creator>
<dc:creator>Tsuyoshi Kaneko</dc:creator>
<dc:creator>Nicole Karam</dc:creator>
<dc:creator>Jaffar M Khan</dc:creator>
<dc:creator>Jan Kovac</dc:creator>
<dc:creator>Uri Landes</dc:creator>
<dc:creator>Jonathon A Leipsic</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Mahesh V Madhavan</dc:creator>
<dc:creator>Moody M Makar</dc:creator>
<dc:creator>Raj R Makkar</dc:creator>
<dc:creator>Mouaz Al Mallah</dc:creator>
<dc:creator>David Meier</dc:creator>
<dc:creator>Thomas Modine</dc:creator>
<dc:creator>Atsushi Okada</dc:creator>
<dc:creator>Roosha K Parikh</dc:creator>
<dc:creator>Radoslaw Parma</dc:creator>
<dc:creator>Dhairya Patel</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:creator>Bernard Prendergast</dc:creator>
<dc:creator>Nishath Quader</dc:creator>
<dc:creator>Michael J Reardon</dc:creator>
<dc:creator>Toby Rogers</dc:creator>
<dc:creator>Lucy M Safi</dc:creator>
<dc:creator>Stephanie L Sellers</dc:creator>
<dc:creator>Sabah Skaf</dc:creator>
<dc:creator>Giuseppe Tarantini</dc:creator>
<dc:creator>Didier Tchetche</dc:creator>
<dc:creator>Nicolas van Mieghem</dc:creator>
<dc:creator>Dee Dee Wang</dc:creator>
<dc:creator>John G Webb</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Steven J Yakubov</dc:creator>
<dc:creator>Victoria Delgado</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Hasan Jilaihawi</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Best Practices for Imaging of Transcatheter Valve Failure: An Update From the Heart Valve Collaboratory</dc:title>
<dc:identifier>pmid:40074470</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.017</dc:identifier>
</item>
<item>
<title>Lessons From Celect: Building Transparency and Trust in Medical Devices</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074469/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):1038-1041. doi: 10.1016/j.jacc.2025.01.002.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074469/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40074469</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.002>10.1016/j.jacc.2025.01.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074469</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Kushal T Kadakia</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lessons From Celect: Building Transparency and Trust in Medical Devices</dc:title>
<dc:identifier>pmid:40074469</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.002</dc:identifier>
</item>
<item>
<title>The Cardiovascular Epidemiology of Smoking: Past, Present, and Future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074468/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):1035-1037. doi: 10.1016/j.jacc.2025.01.017.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074468/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40074468</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.017>10.1016/j.jacc.2025.01.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074468</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Oisin Galvin</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:creator>John W McEvoy</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Cardiovascular Epidemiology of Smoking: Past, Present, and Future</dc:title>
<dc:identifier>pmid:40074468</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.017</dc:identifier>
</item>
<item>
<title>Association Between Cigarette Smoking and Subclinical Markers of Cardiovascular Harm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074467/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Smoking-relevant parameters show strong and dose-response relationships across 3 domains of subclinical markers of cardiovascular harm. The sensitivity of the tested subclinical markers to small increments in cigarette exposure suggests potential value in the regulation of new and existing tobacco products.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):1018-1034. doi: 10.1016/j.jacc.2024.12.032.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cigarette smoking is a strong risk factor for cardiovascular harm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The study sought to explore the detailed relationships between smoking intensity, pack-years, and time since cessation with inflammation, thrombosis, and subclinical atherosclerosis markers of cardiovascular harm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We included 182,364 participants (mean age 58.2 years, 69.0% female) from 22 cohorts of the Cross Cohort Collaboration with self-reported smoking status, including smoking intensity and/or pack-years, and concurrent subclinical marker measurements. Markers were categorized into 3 domains: inflammation (high-sensitivity C-reactive protein, interleukin-6, glycoprotein acetylation), thrombosis (fibrinogen, D-dimer), and subclinical atherosclerosis (coronary artery calcium, carotid intima-media thickness, carotid plaque, and ankle-brachial index). Utilizing multivariate regression models and restricted cubic splines, we assessed associations of smoking status, intensity, pack-years, time since cessation, and subclinical markers.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 15.3% of participants currently smoke (mean 16.7 cigarettes/day, mean 30.0 pack-years), and 34.6% of participants formerly smoked (median 19.0 years since quitting, mean 22.4 pack-years). Participants with a history of smoking showed higher levels of all subclinical markers compared with those who have never smoked, with stronger associations observed in those currently smoke. Among participants who currently smoke, smoking intensity showed a clear dose-response relationship with all markers, except for D-dimer, specifically with incremental 1% to 9% higher levels of subclinical markers per 10 cigarettes. After 20 cigarettes, the patterns appeared to plateau for blood markers, while they continued to increase for atherosclerosis markers. Among those who have ever smoked, robust dose-response relationships were observed for pack-years with all subclinical markers, with incremental 1% to 9% higher levels per 10 pack-years. The dose-response effects persisted after 20 pack-years for all markers, though with a milder slope. Among participants who smoked formerly, there were substantially lower levels of biomarkers with longer time since quitting, and most markers were not different compared with those who have never smoked by 30 years, except for the coronary artery calcium score, which remained 19% higher even beyond quitting after 30 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Smoking-relevant parameters show strong and dose-response relationships across 3 domains of subclinical markers of cardiovascular harm. The sensitivity of the tested subclinical markers to small increments in cigarette exposure suggests potential value in the regulation of new and existing tobacco products.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074467/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40074467</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.032>10.1016/j.jacc.2024.12.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074467</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Zhiqi Yao</dc:creator>
<dc:creator>Erfan Tasdighi</dc:creator>
<dc:creator>Zeina A Dardari</dc:creator>
<dc:creator>Kunal K Jha</dc:creator>
<dc:creator>Ngozi Osuji</dc:creator>
<dc:creator>Tanuja Rajan</dc:creator>
<dc:creator>Ellen Boakye</dc:creator>
<dc:creator>Carlos J Rodriguez</dc:creator>
<dc:creator>Kunihiro Matsushita</dc:creator>
<dc:creator>Eleanor M Simonsick</dc:creator>
<dc:creator>Joao A C Lima</dc:creator>
<dc:creator>Rachel Widome</dc:creator>
<dc:creator>Debbie L Cohen</dc:creator>
<dc:creator>Lawrence J Appel</dc:creator>
<dc:creator>Amit Khera</dc:creator>
<dc:creator>Michael E Hall</dc:creator>
<dc:creator>Suzanne E Judd</dc:creator>
<dc:creator>Shelley A Cole</dc:creator>
<dc:creator>Ramachandran S Vasan</dc:creator>
<dc:creator>Emelia J Benjamin</dc:creator>
<dc:creator>Paulo A Lotufo</dc:creator>
<dc:creator>Isabela M Benseñor</dc:creator>
<dc:creator>Samar R El Khoudary</dc:creator>
<dc:creator>Emma Barinas-Mitchell</dc:creator>
<dc:creator>Imke Janssen</dc:creator>
<dc:creator>Bruce M Psaty</dc:creator>
<dc:creator>Charles B Eaton</dc:creator>
<dc:creator>Michael J LaMonte</dc:creator>
<dc:creator>Peggy M Cawthon</dc:creator>
<dc:creator>Eric S Orwoll</dc:creator>
<dc:creator>Marguerite R Irvin</dc:creator>
<dc:creator>Aruni Bhatnagar</dc:creator>
<dc:creator>Andrew P DeFilippis</dc:creator>
<dc:creator>Omar El-Shahaway</dc:creator>
<dc:creator>Michael J Blaha</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Association Between Cigarette Smoking and Subclinical Markers of Cardiovascular Harm</dc:title>
<dc:identifier>pmid:40074467</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.032</dc:identifier>
</item>
<item>
<title>Transthyretin Amyloid Cardiomyopathy: Wherever Protein Stabilization Leads, Disease Stabilization Follows</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074466/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):1015-1017. doi: 10.1016/j.jacc.2025.01.008.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074466/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40074466</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.008>10.1016/j.jacc.2025.01.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074466</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Justin L Grodin</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transthyretin Amyloid Cardiomyopathy: Wherever Protein Stabilization Leads, Disease Stabilization Follows</dc:title>
<dc:identifier>pmid:40074466</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.008</dc:identifier>
</item>
<item>
<title>Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074465/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In participants with ATTR-CM, acoramidis reduced the composite of ACM or first CVH vs placebo, with an early effect driven by a reduction in CVH. (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy [ATTRibute-CM]; NCT03860935).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):1003-1014. doi: 10.1016/j.jacc.2024.11.042.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed chronic disease associated with progressive heart failure that results in impaired quality of life, repeated hospitalizations, and premature death. Acoramidis is a selective, oral transthyretin stabilizer recently approved by the U.S. Food and Drug Administration for the treatment of ATTR-CM. In a phase 3, randomized, double-blind study (ATTRibute-CM [Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy]), acoramidis was well tolerated and showed clinical efficacy in improving the primary endpoint, a hierarchical combination of all-cause mortality (ACM), cardiovascular-related hospitalization (CVH), N-terminal pro-B-type natriuretic peptide level, and 6-minute walk distance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to characterize the efficacy of acoramidis on ACM and CVH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In ATTRibute-CM, participants with ATTR-CM were randomized 2:1 to receive acoramidis hydrochloride (800 mg twice daily) or placebo for 30 months. Efficacy analyses were conducted in the modified intention-to-treat population (participants with a baseline estimated glomerular filtration rate ≥30 mL/min/1.73 m<sup>2</sup>). CVH and the composite of ACM or first CVH were plotted by using Kaplan-Meier curves and summarized with a stratified Cox proportional hazards model. The annualized frequency of CVH was analyzed by using a negative binomial regression model. Subgroup analyses were conducted for the composite of ACM or first CVH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 632 participants randomized to treatment, 611 (97%) were included in efficacy analyses (acoramidis, n = 409; placebo, n = 202). Compared with placebo, acoramidis reduced the occurrence of the composite of ACM or first CVH (acoramidis, 35.9%; placebo, 50.5%; HR: 0.64; 95% CI: 0.50-0.83; P = 0.0008) and of first CVH (acoramidis, 26.7%; placebo, 42.6%; HR: 0.60; 95% CI: 0.45-0.80; P = 0.0005), with Kaplan-Meier curves separating at month 3 and continuing to diverge through month 30. Annualized frequency of CVH was reduced with acoramidis compared with placebo (acoramidis, 0.22; placebo, 0.45; relative risk ratio: 50%; 95% CI: 0.36-0.70; P &lt; 0.0001). The efficacy of acoramidis on the composite of ACM or first CVH was consistent across subgroups. Acoramidis was well tolerated, with no safety signals of potential clinical concern identified.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In participants with ATTR-CM, acoramidis reduced the composite of ACM or first CVH vs placebo, with an early effect driven by a reduction in CVH. (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy [ATTRibute-CM]; NCT03860935).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074465/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40074465</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.042>10.1016/j.jacc.2024.11.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074465</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Daniel P Judge</dc:creator>
<dc:creator>Kevin M Alexander</dc:creator>
<dc:creator>Francesco Cappelli</dc:creator>
<dc:creator>Marianna Fontana</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:creator>Simon D J Gibbs</dc:creator>
<dc:creator>Martha Grogan</dc:creator>
<dc:creator>Mazen Hanna</dc:creator>
<dc:creator>Ahmad Masri</dc:creator>
<dc:creator>Mathew S Maurer</dc:creator>
<dc:creator>Laura Obici</dc:creator>
<dc:creator>Prem Soman</dc:creator>
<dc:creator>Xiaofan Cao</dc:creator>
<dc:creator>Ted Lystig</dc:creator>
<dc:creator>Jean-François Tamby</dc:creator>
<dc:creator>Suresh Siddhanti</dc:creator>
<dc:creator>Adam Castaño</dc:creator>
<dc:creator>Leonid Katz</dc:creator>
<dc:creator>Jonathan C Fox</dc:creator>
<dc:creator>Kenneth W Mahaffey</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy</dc:title>
<dc:identifier>pmid:40074465</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.042</dc:identifier>
</item>
<item>
<title>Genetic Testing for Cardiovascular Disease: Evidence Grows But Challenges Remain</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074464/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):1000-1002. doi: 10.1016/j.jacc.2025.01.007.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074464/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40074464</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.007>10.1016/j.jacc.2025.01.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074464</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>J Lukas Laws</dc:creator>
<dc:creator>Giovanni E Davogustto</dc:creator>
<dc:creator>Quinn S Wells</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Genetic Testing for Cardiovascular Disease: Evidence Grows But Challenges Remain</dc:title>
<dc:identifier>pmid:40074464</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.007</dc:identifier>
</item>
<item>
<title>Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF: The HuMAIN-HFpEF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40072462/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250314061204&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Among patients with obesity-related HFpEF, treatment with HU6 for 19 weeks led to modest but statistically significant weight loss without significant changes in peak VO2. Larger trials of longer duration are warranted to determine whether longer-term administration of HU6 can improve exercise function, quality of life, and cardiovascular outcomes in this increasingly common disorder.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 12. doi: 10.1001/jamacardio.2025.0103. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Excess body fat plays a pivotal role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF). HU6 is a novel, controlled metabolic accelerator that enhances mitochondrial uncoupling resulting in increased metabolism and fat-specific weight loss.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess efficacy and safety of HU6 in reducing body weight, improving peak volume of oxygen consumption (VO2) and body composition among patients with obesity-related HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The Exploratory Phase 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of HU6 for Subjects With Obese HFpEF (HuMAIN-HFpEF) trial was a multicenter, dose-escalation randomized clinical trial among patients with chronic stable HFpEF and obesity. Data were analyzed from July to October 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: HU6 treatment for 19 weeks, starting at 150 mg per day and potentially up titrated to 450 mg per day based on safety and tolerability vs placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was change in body weight.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 66 participants randomized (mean [SD] age, 64.5 [12] years; 38 female [58%]; mean [SD] weight, 110.9 [22.4] kg), 56 completed the trial. HU6 (vs placebo) significantly decreased weight (between-group difference, -2.86 kg; 95% CI, -4.68 to -1.04 kg; P = .003), total fat mass (between-group difference, -2.96 kg; 95% CI, -4.50 to -1.42 kg; P &lt; .001), and percentage visceral fat (between-group difference,-1.3%; 95% CI, -2.1 to -0.5%; P = .003), with no significant loss of muscle mass. There were no statistically significant changes in peak VO2, 6-minute walk distance, Kansas City Cardiomyopathy Questionnaire score, high-sensitivity C-reactive protein level, N-terminal pro-brain natriuretic peptide level, or diastolic function. Serious adverse events were noted in 5 participants (4 in the HU6 group; 1 in the placebo group), including 1 death, all judged unrelated to treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Among patients with obesity-related HFpEF, treatment with HU6 for 19 weeks led to modest but statistically significant weight loss without significant changes in peak VO2. Larger trials of longer duration are warranted to determine whether longer-term administration of HU6 can improve exercise function, quality of life, and cardiovascular outcomes in this increasingly common disorder.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05284617.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40072462/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250314061204&v=2.18.0.post9+e462414">40072462</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0103>10.1001/jamacardio.2025.0103</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40072462</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Ambarish Pandey</dc:creator>
<dc:creator>Gregory D Lewis</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Andrew J Sauer</dc:creator>
<dc:creator>Sheldon Litwin</dc:creator>
<dc:creator>Kavita Sharma</dc:creator>
<dc:creator>Diane K Jorkasky</dc:creator>
<dc:creator>Elizabeth A Tarka</dc:creator>
<dc:creator>Shaharyar M Khan</dc:creator>
<dc:creator>Dalane W Kitzman</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF: The HuMAIN-HFpEF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:40072462</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0103</dc:identifier>
</item>





























</channel>
</rss>